Excitatory amino acids and Parkinson's disease
- 28 February 1990
- journal article
- other
- Published by Elsevier in Trends in Neurosciences
- Vol. 13 (2) , 46
- https://doi.org/10.1016/0166-2236(90)90066-j
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's diseaseTrends in Neurosciences, 1989
- The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted miceJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1989
- Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channelsEuropean Journal of Pharmacology, 1989
- Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in ratsPharmacology Biochemistry and Behavior, 1989
- Systemic approaches to modifying quinolinic acid striatal lesions in ratsJournal of Neuroscience, 1988
- Quinolinic acid lesions of rat striatum abolish D1- and D2-dopamine receptor-mediated catalepsyBrain Research, 1988
- Behavioural effects of N-methyl-D-aspartate in the anterodorsal striatum of the ratLife Sciences, 1987
- Anti-parkinsonian agents are phencyclidine agonists and N-methyl-aspartate antagonistsEuropean Journal of Pharmacology, 1987
- Intrastriatal injection of dl-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonized by haloperidol and clozapinePsychopharmacology, 1986
- Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptorsNature, 1980